Early benefit assessments Archives — Page 7 of 9 — German Market Access

Another cancer drug by Janssen unlikely to be available in Germany

Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,

On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with

Currently, reserve antibiotics are excluded from a benefit assessment by the G-BA. The G-BA decides whether to accept a new antibiotic onto the

In this post, I’m following up on the key points on the real-world evidence (RWE) data collection in Germany with an IQWiG

In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since

Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in

Welcome! In this post, I am going through the steps on how the G-BA chooses the appropriate comparative therapy (ACT). I conclude

This week, we are having a brief look at two brief reports on PROs recently published by the IQWiG. We’ll cover: As

Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:

This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early